Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNWPMO)

Drug Name

IDH305 Drug Info

Synonyms

DCGDPJCUIKLTDU-SUNYJGFJSA-N; IDH-305; 1628805-46-8; UNII-A791KH7YZW; A791KH7YZW; CHEMBL3947537; SCHEMBL16045032; BDBM247859; CS-8084; HY-104036; US9434719, 466; (R)-4-((S)-1-fluoroethyl)-3-(2-(((S)-1-(4-methyl-2'-(trifluoromethyl)-[3,4'-bipyridin]-6-yl)ethyl)amino)pyrimidin-4-yl)oxazolidin-2-one; (4R)-4-[(1S)-1-fluoroethyl]-3-[2-({(1S)-1-[4-methyl-2'-(trifluoromethyl)[3,4'-bipyridin]-6-yl]ethyl}amino)pyrimidin-4-yl]-1,3-oxazolidin-2-one; C81

Indication

Disease Entry	ICD 11	Status	REF
Advanced malignancy	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

PubChem CID: 90415637
CAS Number: CAS 1628805-46-8
TTD Drug ID: DMNWPMO

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Oxalosuccinate decarboxylase (IDH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ivosidenib	DM8S6T7	Acute myeloid leukaemia	2A60	Approved	[2]
Olutasidenib	DMPH916	Acute myeloid leukaemia	2A60	Approved	[3]
LY3410738	DMFU0H5	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Oxalosuccinate decarboxylase (IDH1)	TTV2A1R	IDHC_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215814.
4	LY3410738, a novel inhibitor of mutant IDH1 is more effective than Ivosidenib and potentiates antileukemic activity of standard chemotherapy in preclinical models of acute myeloid leukemia (AML). Cancer Res 2020;80(16 Suppl):Abstract nr 6417.